Zhao WQ, Li XD, Shi HB, Wu J, Zhao JM, Ji M, Wu CP. CD40 mutant expression and its clinical significance to prognosis in gastric cancer patients.
World J Surg Oncol 2014;
12:167. [PMID:
24885116 PMCID:
PMC4050400 DOI:
10.1186/1477-7819-12-167]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2014] [Accepted: 05/06/2014] [Indexed: 11/29/2022] Open
Abstract
Background
We aimed to detect CD40 mutant expression and evaluate its clinical significance in gastric cancer.
Methods
CD40 mutant expression in 78 cases of gastric cancer tissues, 10 cases of normal gastric tissues, and 10 cases of gastric adenoma tissues by immunohistochemical test. Survival analyses were also performed.
Results
The positive CD40 mutant rate in gastric cancer was 55.1% (43/78). No positive CD40 mutant staining was observed in the normal gastric tissue or the gastric adenoma. CD40 mutants expression was significantly correlated with invasive depth, lymph metastasis, and TNM stage (P <0.05). Cases with negative CD40 mutant expression had a significantly longer median survival time than those with positive CD40 mutant expression (40 vs. 14 months, P <0.05). A lower death risk in negative CD40 mutant cases was observed comparing with positive CD40 mutant cases.
Conclusions
Positive CD40 mutant expression suggests a poorer prognosis of gastric cancer cases.
Collapse